Objective: We investigated the impact of potassium citrate on bone mineral density in patients with idiopathic normocalciuric recur-rent urinary system calcium stones.
Materials and Methods: A total of 30 pa-tients, aged between 18 and 51 years, inclu-ding 16 women and 14 men with personel his-tory of at least 2 kidney stones were enrolled in the study. Standard metabolic, endocrine and 24-hour urine tests were performed. Only tho-se with a diagnosis of idiopathic normocalsiuric calsium stone were included in the study group. None of the patients had any disease that may affect calcium and bone metabolism. The body mass index was calculated for each subject. Die-tary sodium and oxalate intake were limited du-ring study. Total femur and L2-4 bone mineral density and Z-scores were calculated in patients before and after treatment with 60 mEq/day po-tassium citrate for 6-18 months.
Results: The mean ages of men and women were 34.5±8 and 32.18±6 consecutively. BMI of men was 24.8±1.9kg/m2 and women was 22.6±1.5kg/m2 . There were no statistically sig-nificant change in the serum biochemical pa-rameters and urine calcium level after treat-ment (p>0.05). Urine citrate level was signifi-cantly elevated for both genders (p<0.05). L2-4 vertebrate and femur bone mineral density and
Z-score were significantly better after treatment (p<0.05).
Conclusion: Potassium citrate, a systemic alkylating agent can be beneficial to prevent bone mineral density loss in patients with nor-mocalciuric urolithiasis. However prospective studies with longer follow up duration and larger study population is needed to evaluate the efficacy.
Key Words: Potassium citrate, normocalciuria, bone mineral density.
Abstract
Objective: We investigated the impact of potassium citrate on bone mineral density in patients with idiopathic normocalciuric recur-rent urinary system calcium stones.
Materials and Methods: A total of 30 pa-tients, aged between 18 and 51 years, inclu-ding 16 women and 14 men with personel his-tory of at least 2 kidney stones were enrolled in the study. Standard metabolic, endocrine and 24-hour urine tests were performed. Only tho-se with a diagnosis of idiopathic normocalsiuric calsium stone were included in the study group. None of the patients had any disease that may affect calcium and bone metabolism. The body mass index was calculated for each subject. Die-tary sodium and oxalate intake were limited du-ring study. Total femur and L2-4 bone mineral density and Z-scores were calculated in patients before and after treatment with 60 mEq/day po-tassium citrate for 6-18 months.
Results: The mean ages of men and women were 34.5±8 and 32.18±6 consecutively. BMI of men was 24.8±1.9kg/m2 and women was 22.6±1.5kg/m2 . There were no statistically sig-nificant change in the serum biochemical pa-rameters and urine calcium level after treat-ment (p>0.05). Urine citrate level was signifi-cantly elevated for both genders (p<0.05). L2-4 vertebrate and femur bone mineral density and
Z-score were significantly better after treatment (p<0.05).
Conclusion: Potassium citrate, a systemic alkylating agent can be beneficial to prevent bone mineral density loss in patients with nor-mocalciuric urolithiasis. However prospective studies with longer follow up duration and larger study population is needed to evaluate the efficacy.
Key Words: Potassium citrate, normocalciuria, bone mineral density.